

25 June 2024

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Dear Madam,

BIOTRON CLINICAL TRIAL RESULTS WEBINAR

Investor Webinar 11am AEST Wednesday 26 June, 2024

Register using this link:

https://us06web.zoom.us/webinar/register/WN_8uQjMZ3eSxSGyKyimHePaA

Participants may submit questions during registration or during the session


- **BIT225-011 Phase 2 HIV trial met primary objectives in patients who have not achieved full immune reconstitution despite long-term suppressive antiretroviral treatment**
 - BIT225 was safe and generally well tolerated with no deaths or drug-related serious adverse events
 - All trial patients maintained viral suppression throughout the study with statistically significant improvements in immune markers, in line with previous trials
- **BIT225-010 Phase 2 HIV trial in treatment-naïve patients met primary objectives**
 - Suggests unique effect beyond current standard-of-care antiretroviral drugs
- **Detailed results analysis for BIT225-012 trial in Sars-CoV-2 underway**

Biotron CEO and Managing Director, Dr Michelle Miller, and Chief Medical Officer, Dr Stephen Becker, will host a webinar 11am AEST 26 June 2024 to update investors on the positive results from two Phase 2 trials for BIT225 in HIV patients.

The outcomes are in line with previous trials and suggests BIT225 has a unique immune-modifying effect when used with cART.

Interested participants are invited to register using the link above.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn12226